Trials / Completed
CompletedNCT02291783
Phase I, Healthy Subject, Safety, Tolerability and Pharmacokinetic Study of an M1 Agonist to Treat Cognitive Impairment
A Double-Blind, Placebo-Controlled, Single and Multiple Oral Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of HTL0009936 in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 108 (actual)
- Sponsor
- Nxera Pharma UK Limited · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics in young and elderly healthy volunteers of HTL9936, a selective M1 receptor agonist intended for the treatment of cognitive disorders.
Detailed description
The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics in young and elderly healthy volunteers of HTL9936, a selective M1 receptor agonist intended for the treatment of cognitive disorders. This study is a single ascending dose study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HTL0009936 | Single dose |
| DRUG | HTL0009936 placebo | Placebo single dose |
Timeline
- Start date
- 2013-11-01
- Primary completion
- 2014-07-01
- Completion
- 2014-07-01
- First posted
- 2014-11-14
- Last updated
- 2017-06-20
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT02291783. Inclusion in this directory is not an endorsement.